you join Well, good thank you, our and Deb, for us We appreciate call having today. afternoon, everyone.
our start Today, please. growing and in company quarter. first five, reported prior slide of operating the revenue year sequentially units. as $XXX.X up the had X% with record on for for fourth Let's million XX% compared a quarter the a our whole we for over the quarter results each Maravai to and quarter,
Our revenue CleanCap base from vaccines, which over business excludes up the prior was COVID-XX XX% year. revenue,
of prior for EBITDA million $XXX adjusted margin we over record and reported the Our quarter. XX% year, a EBITDA up the XX% adjusted was
and of adjusted adjusted EBITDA share resulted performance per the Our line earnings outstanding share for in top quarter. $X.XX per
have We quarter cash free the million. flows $XXX.X also of in record adjusted
see that to an can you So is solid start. off incredibly XXXX
deliver growth vaccine of on Our the we experienced across COVID base over our business have impressive continues the reflecting the for top products demand few last years. strong to board, tailwinds
We and base global and our momentum research accelerates. have seen, expect cell customer across gene as to development and continued therapy see, mRNA
robust say, six. slide remains, by the market. somewhat was acid to broader underappreciated nucleic and very business Growth Turning the I'd production across
X% of and revenue first in $XXX.X had year-over-year million quarter, acid nucleic Our record up sequentially. production XX% up business the
Excluding base those XX% remarkable grew our COVID-XX-related year-over-year. CleanCap nucleic acid revenues, business a
to customers. creation. toolkit nucleic services production CDMO right importantly, we to of these our an CleanCap business into most Demand a increasing are products. support customers number to driver And base acid on of their are long-term own grow of our XX% uniquely positioned consistently We with as the expected is GMP as focus incorporating services key continue this RNA value messenger for
and programs We are other existing our business incorporated have side also the nice new molecules observed into customers. and traction the of product both CleanCap by on new small as
materials base customers come. technology continue the years and while drive to unique in of customer vitro our GMP raw bring growing messenger to help to quality a other RNA our CleanCap across programs to for transcription These messenger opportunity reactions. RNA to and newest value improve should our have inclusion improve critical We providing manufactured
that week, immunity on for on XXXX this know and variables, the We expectations of a Journal impact demand waning for ongoing remains FDA vaccines, end-user vaccine the great severity. the a an worldwide seven. American disease balance demand following slide uncertainty on of the as Medical hesitancy leaders their to and of with senior of COVID-XX The the concern of boosters primary the focus COVID-XX Earlier points. clinical there's for writing deal for next made relates dynamic it to highly of vaccine number impact vaccines. space including ultimate spread potential Turning demand ultimate XXXX And the on basis. variants and will and the of what the severity, its for Association be in around
the that presence is is change following have the peak SARS-CoV-X toward pandemic that, well couple and circulate we normal of for will most that vaccination." scenario it us First, will the time accept now that for may as saying compositions recall variants moving influenza outcome for foreseeable doses predicted are primary likely that seasonal vaccine COVID-XX a exact secondly, include of that who Those And reflect new vaccination need and The alongside the following then in that you will new circulation. by have long-term future. years the to of to years. conclude is the globally annual both is the this virus to "Society future COVID-XX annually been last the normal booster the authors
expect will point. demand this continue forward, uncertainties variability. though for meaningful about current regarding to even landscape that remains unclear And customers and Now from demand our the for this statements their to the contributor to future vaccines the revenue Maravai vaccines of reflect demand COVID-XX we recent period. of some We direct other fully be variable COVID-XX for exposure manufacturers with XXXX exact at is a versions market the the period from going can't of lose sight evidence own the for
discussed early we products, from by demand this that guidance such XXXX is are and our and revenues, our Maravai maintaining biggest of which year-end potential provided As CleanCap customers we commercialized that is and manufacturing entrants requirements the development from new growth revenue, XXXX the announced for are orders as that you XX% market means our a on we book phase rate as forecast on between levels. used already year, and is of being next-generation based CureVac. figures estimated call XX% previously to This February, overall order specific. customers we over say are earnings COVID combination here for done growth end for CleanCap just the our those can later customers, our And in different and material GSK we who estimated be represent our believe that for These vaccines current plans. determine are demand from COVID-XX other for COVID-XX-related uses. reaffirming collaboration revenue we XXXX since work interchangeably helps customers in This growth which on-market by to
to and yet So reasons of for be. our the from vaccine others, production are expected a above into not levels customers and COVID-XX sight largest that we their overall what XXXX have were line specific cited do
mRNA and and continuing quarter a solutions, As to our be now customer-focused an know to that continue they our variety new earnings vaccine of evolving on will rapidly concern. the our with COMIRNATY is boosters real-time and What modifications. still recent XXXX vaccines Recognizing that truly is example, designs invest direct of factors, in flexible support youngest to We're and COVID-XX that revenue we on believe and of can expanding they a control: things the will right provide new the COVID which to do just Pfizer call. in development position vaccine that expect development growth, needs. people rapid design that most their that innovating manufacturing mostly of leadership the only for vaccinations for support a for and guidance market generations outside pace platform longer-term children subject customers' that most control. portfolio, focused And at excited we are technology the COVID-XX in commented fourth business during we about; particular we booster the those demand and base ways include operations, focus variants product of provides our
Now turning slide eight. to
are bullish base. One blue-chip on of nucleic reasons our we the acid our customer global so production is business
we category, by with in customers potentially estimate transformative one the pharma our of XX in R&D drug we at collaborating development that the XX top from to program span on large at the Notably, and mRNA discovery are XXXX. category, companies biotech they platforms large pharma. Looking spenders least of out spectrum RNA to innovative manufacturing
the in for stay to mRNA market and and As is CleanCap durable disease solid both I've right that Maravai vaccines with here of of we said piece and a meaningful before, infectious believe a this action way. in are thick mRNA therapeutics. the
slide nine. Turning now to
include are or technology. into dive the these for the preclinical therapeutics name are this are therapies clinical including and work that underway. cancer, cancers our is messenger tackling oncology Given RNA such RNA of approximately treatment are other time using an trials programs year Through neck conferences, and and programs with highlight indications to cancer are and utilizing the messenger therapeutics. that clinical preclinical with we AACR we that ASCO, know on the working a cancer pancreatic of the we've and deep involved some should cell as thought we and These XX% that a consultant, of we messenger and head completed through roughly oncology cancer, few. XXX development programs vaccines RNA just several trials Of for or CleanCap, HPV-associated melanoma, XX outside of exciting key through
they programs their through the messenger two future an these days in road phase trials, are applications for preclinical of RNA. early map still exciting While in provide
programs cardiovascular diseases includes and mRNA as of therapeutics and human include And such using course, number autoimmune as issues this a vaccines. RNA well for of vaccines coronavirus like diseases, infectious disorders. XXX influenza, for additional other Ebola metabolic health messenger The number for Zika CleanCap as shingles, disease
slide to business. safety biologics turning in XX Now testing our
in Our clearance products. customers innovative providing gene biopharmaceutical support and their that the process-related manufacturing therapy, safety purity ensure products and drug help by our and high-growth with vaccines services business viral in solutions offering markets analytics, of and this biologics along cell prediction
from revenue Safety kits up demand by our first strong host-cell for last XX% Our a revenue industry-leading the Coli new and revenue was protein Testing year. impurity Biologic and notably growth $XX.X ELISA was nearly specifically driven saw This growth in portfolio, CHO primarily of quarter. and record our A our strong kits, which E. quarter testing set in million Protein
performance product also We and automation MockV lines. from had solid our
customers of products. range We gain the for our wide continue new to testing safety biologic
Ella just superior needs. automation technical we develop on to immunoassay with announced a scale into efficient to catalog and quality customers purity support the plan of us process This and entered products provides launch protein XXX testing. for proprietary the for an the the cell to our programs. with Additionally, solution agreements the assays biologics XG offerings ensure our of and fast assay a number new business bioprocess testing to products to in to meet most of Notably, platform. purity collaboration their ProteinSimple and further assay continuously Simple and highest HEK custom Bio-Techne's automated and services comprehensive biologics host customers' innovate We support, offer and our Plex
slide to organizational updates. moving XX on and Now some
In Maravai. Deb Barbara me. happy this business will president, including and leadership global Deb equity us reporting company's goals. also investments, drive mergers has as Deb created acquisitions will integration First, manage for and and team. our strategy role, and development, of company's development business our the function, the strategic welcome leading oversight for vice joined to newly all are strategy April growth to in acquisition planning and we responsibility to Deb
science roles. not you of components, industry. familiar sciences years of assays acids our an as variety supplier incredibly of her important the look differentiate trusted experience life she itself playing biologics Maravai as Deb, for over development forward and has a to team and on I those For continues of and to role a nucleic life XX with business scale
acquisition is going the of the integration well. Second, MyChem
used TriLink's teams. commercial and and of We in messenger diagnostics development are their manufacturing. our cell extends RNA activities addition molecular in the actively manufacturing are and with MyChem therapy, critical capabilities of R&D that gene raw merging product The materials
end, quality RNA we customers. investment ever to our more in facilities committed scale this closely innovation the and our will later are we're and nicely, our partner with expansion as plans Kevin operations, Third, messenger progressing R&D systems call. and our expand this on facility To in increasing
expect site half of Flanders later call Our phase and this year, of two XXXX. Diego, project nucleic to phase in on in acid occupancy one we production schedule, the have the occupancy San first expansion, which with the this project nearby is we for
and spectrometry will customized than of operational automation facilities. are make small first suite been It testing investments of building the our the Carolina, will manufacturing other to our a mass GMP molecule flow R&D, to room Leland, By the us new footage rooms. upgrades. moving in more our Wateridge, capacity and API providing optimize enhance example capacity year. is with an platform into As square current our process we commercial expanding two provide continue and will further progressing of our is some while packaging framed culture a manufacturing and facility site one manufacturing a we Likewise, kit excellence the of process nicely. new Extensive safety growth date base doubles here significantly is toward reminder, cold storage cell specialized GMP moving at capacity. incorporated to design This North adding business. Southport move-in clean phase how laboratory has with new fully production additional future to facilities support the from to These both The Flanders for center further operations accelerate analysis for increase operations. new relocation will in and to The the biologics and our the work by rest growth. and a provide end of state-of-the-art increase CleanCap facility design
additional remain We in growth to pursuing sometime to active XXXX. opportunities look announce forward being and inorganic acquisitions able in also
performance expand so serve customer our reach ask now that international cover more I'll and committed our directly raw We as global may our to first our our details ability material we our specialized we expanding to some are to key XXXX and Kevin? a to quarter actively Kevin footprint improve supplier, on are base. guidance. working
